MovDisordV3, Main, Exploration, bibRecord, 005163

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Identifieur interne : 005163 ( Main/Exploration ); précédent : 005162; suivant : 005164

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Auteurs : Olivier Rascol [France] ; K. Sieradzan [Royaume-Uni] ; H. Peyro-Saint-Paul [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; J. M. Senard [France] ; P. Ladure [France] ; J. L. Montastruc [France] ; A. Lees [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 1998.

RBID : Pascal:98-0354352

Descripteurs français

Pascal (Inist)
- Ophtalmoplégie supranucléaire, Etude double insu, Randomisation, Essai croisé, Efaroxan, Agoniste, Récepteur α2-adrénergique, Chimiothérapie, Motricité, Traitement, Adulte.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Agonist, Chemotherapy, Crossover study, Double blind study, Efaroxan, Motricity, Randomization, Supranuclear ophthalmoplegia, Treatment, α2-Adrenergic receptor.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 002F69
to stream PascalFrancis, to step Curation: 003855
to stream PascalFrancis, to step Checkpoint: 003030
to stream Main, to step Merge: 008154
to stream Main, to step Curation: 005163

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Sieradzan, K" sort="Sieradzan, K" uniqKey="Sieradzan K" first="K." last="Sieradzan">K. Sieradzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Manchester Royal Infirmary</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Neurology, Manchester Royal Infirmary</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peyro Saint Paul, H" sort="Peyro Saint Paul, H" uniqKey="Peyro Saint Paul H" first="H." last="Peyro-Saint-Paul">H. Peyro-Saint-Paul</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Boulogne</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ladure, P" sort="Ladure, P" uniqKey="Ladure P" first="P." last="Ladure">P. Ladure</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Boulogne</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0354352</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0354352 INIST</idno>
<idno type="RBID">Pascal:98-0354352</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002F69</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003855</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003030</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Rascol O:efaroxan:an:alpha</idno>
<idno type="wicri:Area/Main/Merge">008154</idno>
<idno type="wicri:Area/Main/Curation">005163</idno>
<idno type="wicri:Area/Main/Exploration">005163</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Sieradzan, K" sort="Sieradzan, K" uniqKey="Sieradzan K" first="K." last="Sieradzan">K. Sieradzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Manchester Royal Infirmary</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Neurology, Manchester Royal Infirmary</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peyro Saint Paul, H" sort="Peyro Saint Paul, H" uniqKey="Peyro Saint Paul H" first="H." last="Peyro-Saint-Paul">H. Peyro-Saint-Paul</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Boulogne</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ladure, P" sort="Ladure, P" uniqKey="Ladure P" first="P." last="Ladure">P. Ladure</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Boulogne</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
<wicri:noRegion>Institut de Recherche P. Fabre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Agonist</term>
<term>Chemotherapy</term>
<term>Crossover study</term>
<term>Double blind study</term>
<term>Efaroxan</term>
<term>Motricity</term>
<term>Randomization</term>
<term>Supranuclear ophthalmoplegia</term>
<term>Treatment</term>
<term>α2-Adrenergic receptor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ophtalmoplégie supranucléaire</term>
<term>Etude double insu</term>
<term>Randomisation</term>
<term>Essai croisé</term>
<term>Efaroxan</term>
<term>Agoniste</term>
<term>Récepteur α2-adrénergique</term>
<term>Chimiothérapie</term>
<term>Motricité</term>
<term>Traitement</term>
<term>Adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Midi-Pyrénées</li>
</region>
<settlement><li>Londres</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name>
</noRegion>
<name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
<name sortKey="Ladure, P" sort="Ladure, P" uniqKey="Ladure P" first="P." last="Ladure">P. Ladure</name>
<name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<name sortKey="Peyro Saint Paul, H" sort="Peyro Saint Paul, H" uniqKey="Peyro Saint Paul H" first="H." last="Peyro-Saint-Paul">H. Peyro-Saint-Paul</name>
<name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Sieradzan, K" sort="Sieradzan, K" uniqKey="Sieradzan K" first="K." last="Sieradzan">K. Sieradzan</name>
</noRegion>
<name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005163 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005163 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:98-0354352
   |texte=   Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri